Following closing of its transaction with Telix Pharmaceuticals, ImaginAb, Inc. will be focused on developing its lead imaging candidate, CD8 ImmunoPET, which is currently in Phase 2 clinical trials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback